L8S Stock Overview
Engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Grace Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.78 |
| 52 Week High | US$3.14 |
| 52 Week Low | US$1.83 |
| Beta | 1.52 |
| 11 Month Change | 4.51% |
| 3 Month Change | 25.23% |
| 1 Year Change | 25.23% |
| 33 Year Change | -67.14% |
| 5 Year Change | -96.59% |
| Change since IPO | -99.25% |
Recent News & Updates
Recent updates
Shareholder Returns
| L8S | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -2.4% | -2.2% |
| 1Y | 25.2% | -13.3% | 13.3% |
Return vs Industry: L8S exceeded the German Pharmaceuticals industry which returned -12.8% over the past year.
Return vs Market: L8S exceeded the German Market which returned 13.6% over the past year.
Price Volatility
| L8S volatility | |
|---|---|
| L8S Average Weekly Movement | 10.6% |
| Pharmaceuticals Industry Average Movement | 7.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: L8S's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: L8S's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | n/a | Prashant Kohli | www.acastipharma.com |
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company’s lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia.
Grace Therapeutics, Inc. Fundamentals Summary
| L8S fundamental statistics | |
|---|---|
| Market cap | €28.81m |
| Earnings (TTM) | -€10.49m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.7x
P/E RatioIs L8S overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| L8S income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$11.45m |
| Earnings | -US$11.45m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.13 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did L8S perform over the long term?
See historical performance and comparison